Caplin Point Laboratories informs about un-audited financial results

05 Nov 2025 Evaluate
Further to intimation dated 29th October, 2025 Caplin Point Laboratories has informed that the Board of Directors, at its meeting held today i.e. 5th November 2025, has approved the following: 1. Approved the Un-audited standalone and consolidated financial results and the Limited Review Report (Annexure-1) of the Company as per Indian Accounting Standards for the quarter and half year ended 30th September, 2025. They also enclosed a Press Release issued by the Company (Annexure 2) and an investor presentation in this regard (Annexure 3). 2. Approved the Appointment of Ashok Partheeban (DIN: 02507261) as an Additional Director and Vice-Chairman of the Company with effect from 5th November 2025 and whose term is liable to retirement by rotation, subject to the approval of shareholders; etc.

The above information is a part of company’s filings submitted to BSE.  

Caplin Point Lab Share Price

1823.50 -30.70 (-1.66%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×